7 November 2017 - Biocon´s partner Mylan has resubmitted the marketing authorisation applications for our proposed biosimilar trastuzumab and pegfilgrastim with the EMA as per the administrative protocol. 

This follows the earlier withdrawal of both applications in response to the audit of our aseptic drug product facility by the designated European authority. 

Biocon has completed the corrective and preventive actions, including the facility modifications, in response to the audit observations and expects these to be verified during re-inspection.

Read Biocon press release